Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Scorpio2on Jun 27, 2018 6:13pm
110 Views
Post# 28240733

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Missed Opportunity... Again

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Missed Opportunity... AgainAll I can say is that yes, , he is probably unfit in some areas for the job based upon our past experience with him but more importantly I do think there is a  backroom deal that has been agreed to by a pharma (i.e. Merck) that has basically said to him, keep on doing what you are doing, fly under the radar for now, prove up the science and then we will fund you (if you need it ) to advance the science but we will eventually buy you out if you got the goods. No way to prove it...all my speculation but that's what I think is going to happen.
Bullboard Posts